S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

Immunocore (IMCR) Stock Price, News & Analysis

$67.41
+0.19 (+0.28%)
(As of 03/1/2024 ET)
Today's Range
$66.73
$68.94
50-Day Range
$65.57
$75.36
52-Week Range
$42.21
$76.98
Volume
752,643 shs
Average Volume
330,791 shs
Market Capitalization
$3.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.85

Immunocore MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
11.0% Upside
$74.85 Price Target
Short Interest
Bearish
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Immunocore in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$305,769 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

Medical Sector

869th out of 950 stocks

Biological Products, Except Diagnostic Industry

141st out of 153 stocks


IMCR stock logo

About Immunocore Stock (NASDAQ:IMCR)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

IMCR Stock Price History

IMCR Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Key Takeaways From Immunocore Hldgs Analyst Ratings
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Immunocore FY 2023 Earnings Preview
Immunocore (IMCR) Set to Announce Earnings on Wednesday
Immunocore Holdings Ltd (IMCR)
Immunocore Holdings PLC ADR IMCR
See More Headlines
Receive IMCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/02/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMCR
Fax
N/A
Employees
408
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.85
High Stock Price Target
$91.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+11.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$-50,990,000.00
Pretax Margin
-24.41%

Debt

Sales & Book Value

Annual Sales
$249.43 million
Book Value
$7.54 per share

Miscellaneous

Free Float
46,151,000
Market Cap
$3.30 billion
Optionable
Optionable
Beta
0.91
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Bahija Jallal Ph.D. (Age 62)
    CEO & Director
    Comp: $1.42M
  • Mr. Brian R. Di Donato M.B.A. (Age 57)
    CFO & Head of Strategy
  • Ms. Annelise Vuidepot Ph.D.
    CTO and Head of Pipeline & Platform Research
  • Clayton Robertson
    Head of Investor Relations
  • Ms. Lily Margaret Hepworth
    General Counsel & Company Secretary
  • Ms. Amy Judge-Prein
    Chief Compliance Officer
  • Mr. Sébastien Desprez
    Head of Communications
  • Ms. Tina St. Leger (Age 56)
    Chief Human Resources Officer & Director
  • Dr. David Berman M.D. (Age 53)
    Ph.D., Head of Research & Development
  • Ms. Debra Nielsen
    Chief of Staff














IMCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunocore stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMCR shares.
View IMCR analyst ratings
or view top-rated stocks.

What is Immunocore's stock price target for 2024?

14 brokerages have issued 1 year price objectives for Immunocore's shares. Their IMCR share price targets range from $16.00 to $91.00. On average, they predict the company's share price to reach $74.85 in the next twelve months. This suggests a possible upside of 11.0% from the stock's current price.
View analysts price targets for IMCR
or view top-rated stocks among Wall Street analysts.

How have IMCR shares performed in 2024?

Immunocore's stock was trading at $68.32 at the beginning of 2024. Since then, IMCR stock has decreased by 1.3% and is now trading at $67.41.
View the best growth stocks for 2024 here
.

When is Immunocore's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our IMCR earnings forecast
.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) announced its earnings results on Wednesday, February, 28th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.12. The business had revenue of $70.16 million for the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative trailing twelve-month return on equity of 15.78% and a negative net margin of 22.48%. The firm's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.63) earnings per share.

What ETFs hold Immunocore's stock?
When did Immunocore IPO?

(IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

Who are Immunocore's major shareholders?

Immunocore's stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.02%), Bellevue Group AG (1.99%), Fiera Capital Corp (1.73%), Braidwell LP (1.25%), Principal Financial Group Inc. (0.99%) and TD Asset Management Inc (0.71%).
View institutional ownership trends
.

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMCR) was last updated on 3/2/2024 by MarketBeat.com Staff